

Milo Gatti

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8625940/publications.pdf>

Version: 2024-02-01

58
papers

938
citations

489802

18
h-index

620720

26
g-index

58
all docs

58
docs citations

58
times ranked

814
citing authors

#	ARTICLE	IF	CITATIONS
1	An evidence-based multidisciplinary approach focused at creating algorithms for targeted therapy of infection-related ventilator associated complications (IVACs) caused by Enterobacterales in critically ill adult patients. <i>Expert Review of Anti-Infective Therapy</i> , 2022, 20, 331-352.	2.0	7
2	Crystal nephropathy and amoxicillin: insights from international spontaneous reporting systems. <i>Journal of Nephrology</i> , 2022, 35, 1017-1027.	0.9	4
3	Successful Treatment of Bacteremia and Ventilator-Associated Pneumonia Caused by KPC/OXA-48-like <i>Klebsiella pneumoniae</i> Co-Producer with a Continuous Infusion of High-Dose Meropenem Plus Fosfomycin Guided by Real-Time Therapeutic Drug Monitoring. <i>Infectious Disease Reports</i> , 2022, 14, 88-92.	1.5	3
4	Real-Time Optimization of Pharmacodynamic Target Attainment at Infection Site during Treatment of Post-Neurosurgical Ventriculitis Caused by Carbapenem-Resistant Gram Negatives with Ceftazidime+Avibactam-Based Regimens: A Report of Two Cases. <i>Microorganisms</i> , 2022, 10, 154.	1.6	13
5	Real-World Comparison of Isavuconazole and Voriconazole in Terms of the Need for Dosage Adjustments Guided by Clinical Pharmacological Advice During Primary Prophylaxis of Invasive Fungal Infections in Pediatric Patients with Hemato-Oncological Malignancies. <i>Therapeutic Drug Monitoring</i> , 2022, 44, 641-650.	1.0	4
6	Orthopaedic Implant-Associated Staphylococcal Infections: A Critical Reappraisal of Unmet Clinical Needs Associated with the Implementation of the Best Antibiotic Choice. <i>Antibiotics</i> , 2022, 11, 406.	1.5	12
7	Clinical outcome in solid organ transplant recipients affected by COVID-19 compared to general population: a systematic review and meta-analysis. <i>Clinical Microbiology and Infection</i> , 2022, 28, 1057-1065.	2.8	33
8	An Evidence-Based Multidisciplinary Approach Focused on Creating Algorithms for Targeted Therapy of Infection-Related Ventilator-Associated Complications (IVACs) Caused by <i>Pseudomonas aeruginosa</i> and <i>Acinetobacter baumannii</i> in Critically Ill Adult Patients. <i>Antibiotics</i> , 2022, 11, 33.	1.5	15
9	Liver Injury with Nintedanib: A Pharmacovigilance+Pharmacokinetic Appraisal. <i>Pharmaceuticals</i> , 2022, 15, 645.	1.7	5
10	Expert clinical pharmacological advice may make an antimicrobial TDM program for emerging candidates more clinically useful in tailoring therapy of critically ill patients. <i>Critical Care</i> , 2022, 26, .	2.5	41
11	Adverse events with sacubitril/valsartan in the real world: emerging signals to target preventive strategies from the FDA adverse event reporting system. <i>European Journal of Preventive Cardiology</i> , 2021, 28, 983-989.	0.8	29
12	Serious adverse events with tocilizumab: Pharmacovigilance as an aid to prioritize monitoring in COVID+19. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 1533-1540.	1.1	40
13	Assessment of adverse reactions to \pm -lipoic acid containing dietary supplements through spontaneous reporting systems. <i>Clinical Nutrition</i> , 2021, 40, 1176-1185.	2.3	18
14	Ceftolozane/tazobactam exposure in critically ill patients undergoing continuous renal replacement therapy: a PK/PD approach to tailor dosing. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 199-205.	1.3	10
15	Serotonin syndrome by drug interactions with linezolid: clues from pharmacovigilance-pharmacokinetic/pharmacodynamic analysis. <i>European Journal of Clinical Pharmacology</i> , 2021, 77, 233-239.	0.8	23
16	Should the Clinical Pharmacologist Play a Role in the Multidisciplinary Team Managing Severe Necrotizing Soft-Tissue Infections?. <i>Clinical Pharmacokinetics</i> , 2021, 60, 403-407.	1.6	3
17	Influenza Vaccination and Myo-Pericarditis in Patients Receiving Immune Checkpoint Inhibitors: Investigating the Likelihood of Interaction through the Vaccine Adverse Event Reporting System and VigiBase. <i>Vaccines</i> , 2021, 9, 19.	2.1	11
18	Serious adverse events with novel beta-lactam/beta-lactamase inhibitor combinations: a large-scale pharmacovigilance analysis. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2021, 40, 1169-1176.	1.3	8

#	ARTICLE	IF	CITATIONS
19	Drug Repurposing in the COVID-19 Era: Insights from Case Studies Showing Pharmaceutical Peculiarities. <i>Pharmaceutics</i> , 2021, 13, 302.	2.0	24
20	Clinically Significant Drug Interactions Between Psychotropic Agents and Repurposed COVID-19 Therapies. <i>CNS Drugs</i> , 2021, 35, 345-384.	2.7	8
21	Pharmacokinetic/pharmacodynamic target attainment in critically ill renal patients on antimicrobial usage: focus on novel beta-lactams and beta lactams/beta-lactamase inhibitors. <i>Expert Review of Clinical Pharmacology</i> , 2021, 14, 583-599.	1.3	31
22	Quality of care indicators in the MAnageMent of BLOOdstream infections caused by Enterobacteriaceae (MAMBOO-E study): state of the art and research agenda. <i>International Journal of Antimicrobial Agents</i> , 2021, 57, 106320.	1.1	6
23	Breakthrough invasive fungal infection after liver transplantation in patients on targeted antifungal prophylaxis: A prospective multicentre study. <i>Transplant Infectious Disease</i> , 2021, 23, e13608.	0.7	11
24	Bone fracture as a novel immune-related adverse event with immune checkpoint inhibitors: Case series and large-scale pharmacovigilance analysis. <i>International Journal of Cancer</i> , 2021, 149, 675-683.	2.3	11
25	European List of Essential Medicines for Medical Education: a protocol for a modified Delphi study. <i>BMJ Open</i> , 2021, 11, e045635.	0.8	5
26	An Evidence-Based Multidisciplinary Approach Focused at Creating Algorithms for Targeted Therapy of BSIs, cUTIs, and cIAIs Caused by Enterobacteriales in Critically Ill Adult Patients. <i>Infection and Drug Resistance</i> , 2021, Volume 14, 2461-2498.	1.1	14
27	Fluoroquinolones and Aortic Disease. <i>JAMA Internal Medicine</i> , 2021, 181, 881.	2.6	0
28	Antimicrobial Dose Reduction in Continuous Renal Replacement Therapy: Myth or Real Need? A Practical Approach for Guiding Dose Optimization of Novel Antibiotics. <i>Clinical Pharmacokinetics</i> , 2021, 60, 1271-1289.	1.6	27
29	Janus Kinase Inhibitors and Coronavirus Disease (COVID)-19: Rationale, Clinical Evidence and Safety Issues. <i>Pharmaceutics</i> , 2021, 14, 738.	1.7	29
30	Continuous versus intermittent infusion of antibiotics in Gram-negative multidrug-resistant infections. <i>Current Opinion in Infectious Diseases</i> , 2021, 34, 737-747.	1.3	28
31	Serious adverse events with tedizolid and linezolid: pharmacovigilance insights through the FDA adverse event reporting system. <i>Expert Opinion on Drug Safety</i> , 2021, 20, 1421-1431.	1.0	9
32	Evidence and Current Use of Levosimendan in the Treatment of Heart Failure: Filling the Gap. <i>Drug Design, Development and Therapy</i> , 2021, Volume 15, 3391-3409.	2.0	11
33	Breakthrough invasive fungal infections in liver transplant recipients exposed to prophylaxis with echinocandins vs other antifungal agents: A systematic review and meta-analysis. <i>Mycoses</i> , 2021, 64, 1317-1327.	1.8	3
34	Real-World Use of Dalbavancin in the Era of Empowerment of Outpatient Antimicrobial Treatment: A Careful Appraisal Beyond Approved Indications Focusing on Unmet Clinical Needs. <i>Drug Design, Development and Therapy</i> , 2021, Volume 15, 3349-3378.	2.0	34
35	A Proof of Concept of the Role of TDM-Based Clinical Pharmacological Advices in Optimizing Antimicrobial Therapy on Real-Time in Different Paediatric Settings. <i>Frontiers in Pharmacology</i> , 2021, 12, 755075.	1.6	6
36	A descriptive case series of pharmacokinetic/pharmacodynamic target attainment and microbiological outcome in critically ill patients with documented severe extensively drug-resistant <i>Acinetobacter baumannii</i> bloodstream infection and/or ventilator-associated pneumonia treated with cefiderocol. <i>Journal of Global Antimicrobial Resistance</i> , 2021, 27, 294-298.	0.9	44

#	ARTICLE	IF	CITATIONS
37	Suboptimal drug exposure leads to selection of different subpopulations of ceftazidime-avibactam-resistant <i>Klebsiella pneumoniae</i> carbapenemase-producing <i>Klebsiella pneumoniae</i> in a critically ill patient. <i>International Journal of Infectious Diseases</i> , 2021, 113, 213-217.	1.5	15
38	Usefulness of therapeutic drug monitoring in estimating the duration of dalbavancin optimal target attainment in staphylococcal osteoarticular infections: a proof-of-concept. <i>International Journal of Antimicrobial Agents</i> , 2021, 58, 106445.	1.1	19
39	Assessment of a PK/PD Target of Continuous Infusion Beta-Lactams Useful for Preventing Microbiological Failure and/or Resistance Development in Critically Ill Patients Affected by Documented Gram-Negative Infections. <i>Antibiotics</i> , 2021, 10, 1311.	1.5	47
40	Real-life experience with compassionate use of cefiderocol for difficult-to-treat resistant <i>Pseudomonas aeruginosa</i> (DTR-P) infections. <i>JAC-Antimicrobial Resistance</i> , 2021, 3, dlab188.	0.9	38
41	Impact of Maximizing C _{ss} /MIC Ratio on Efficacy of Continuous Infusion Meropenem Against Documented Gram-Negative Infections in Critically Ill Patients and Population Pharmacokinetic/Pharmacodynamic Analysis to Support Treatment Optimization. <i>Frontiers in Pharmacology</i> , 2021, 12, 781892.	1.6	12
42	Development of a Network-Based Signal Detection Tool: The COVID-19 Adversome in the FDA Adverse Event Reporting System. <i>Frontiers in Pharmacology</i> , 2021, 12, 740707.	1.6	5
43	Adaptive trials of new antimicrobials for infections with carbapenem-resistant, Gram-negative bacteria. <i>Lancet Infectious Diseases</i> , The, 2020, 20, 24.	4.6	4
44	The Complex Management of Atrial Fibrillation and Cancer in the COVID-19 Era: Drug Interactions, Thromboembolic Risk, and Proarrhythmia. <i>Current Heart Failure Reports</i> , 2020, 17, 365-383.	1.3	17
45	Risk of bradyarrhythmia related to ticagrelor: A systematic review and meta-analysis. <i>Pharmacological Research</i> , 2020, 160, 105089.	3.1	2
46	Lessons to be Learnt from Real-World Studies on Immune-Related Adverse Events with Checkpoint Inhibitors: A Clinical Perspective from Pharmacovigilance. <i>Targeted Oncology</i> , 2020, 15, 449-466.	1.7	86
47	Liver Injury with Ulipristal Acetate: Exploring the Underlying Pharmacological Basis. <i>Drug Safety</i> , 2020, 43, 1277-1285.	1.4	25
48	Pharmacokinetic analysis investigating gentamicin dosing in a major burned patient complicated by septic shock. <i>Journal of Chemotherapy</i> , 2020, 32, 208-212.	0.7	2
49	Assessing the association between fluoroquinolones and emerging adverse drug reactions raised by regulatory agencies: An umbrella review. <i>European Journal of Internal Medicine</i> , 2020, 75, 60-70.	1.0	25
50	In vivo acquisition and risk of inter-species spread of bla KPC-3-plasmid from <i>Klebsiella pneumoniae</i> to <i>Serratia marcescens</i> in the lower respiratory tract. <i>Journal of Medical Microbiology</i> , 2020, 69, 82-86.	0.7	5
51	Reply-Letter to the editor - The valuable support of spontaneous reporting systems in exploring safety profile of dietary supplements. <i>Clinical Nutrition</i> , 2020, 39, 3854-3855.	2.3	1
52	Relationship between adverse drug reactions to antibacterial agents and the <i>Klebsiella pneumoniae</i> carbapenemase-producing (KPC) <i>Klebsiella pneumoniae</i> outbreak: insight from a pharmacovigilance study. <i>BMC Pharmacology & Toxicology</i> , 2019, 20, 65.	1.0	5
53	Comparative Effectiveness and Safety of Direct Oral Anticoagulants: Overview of Systematic Reviews. <i>Drug Safety</i> , 2019, 42, 1409-1422.	1.4	13
54	Intensive multidisciplinary management in critical care patients affected by severe necrotizing soft tissue infections: a cooperative method to improve the efficacy of treatment. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2019, 38, 1153-1162.	1.3	17

#	ARTICLE	IF	CITATIONS
55	FreeStyle Libre flash glucose monitoring system in pregnant woman with type 1 diabetes: a focus on accuracy. <i>Acta Diabetologica</i> , 2019, 56, 969-970.	1.2	0
56	Feasibility of FreeStyle Libre Flash Glucose Monitoring System in pregnant woman affected by type 1 diabetes. <i>Acta Diabetologica</i> , 2019, 56, 481-483.	1.2	5
57	Septic shock due to NSTI caused by <i>Actinomyces Turicensis</i> : the role of clinical pharmacology. Case report and review of the literature. <i>Journal of Chemotherapy</i> , 2017, 29, 372-375.	0.7	6
58	lbrutinib: from bench side to clinical implications. <i>Medical Oncology</i> , 2015, 32, 225.	1.2	9